← Back to Clinical Trials
Recruiting Phase 1 NCT07299084
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
Trial Parameters
Condition Diabetes Mellitus, Type 2
Sponsor Eli Lilly and Company
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 40
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2026-01-14
Completion 2026-10
All Conditions
Interventions
Tirzepatide
Brief Summary
The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal. Ultrasound will be used to check the stomach content after a test meal.
Eligibility Criteria
Inclusion Criteria: * Meet one of the following criteria: * Have type 2 diabetes * Have obesity * Have overweight with at least one health issue related to weight but without type 2 diabetes Exclusion Criteria: * Have a condition that affects how their stomach empties * Have had weight loss surgery * Have type 1 diabetes * Have any major medical conditions or histories that could interfere with the study
Related Trials
NCT06638567
Postoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site In
View Trial →
NCT07299084
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food
View Trial →
NCT06423729
Effect of Nicorandil in Type 2 Diabetic Obese Patients
View Trial →